Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 39   

Articles published

ARNA 2.27 -0.12 (-5.02%)
price chart
Arena Pharmaceuticals Inc (NASDAQ:ARNA) Puts Another Treatment in the Pipeline
New drugs may make or break a pharmaceutical competitor, so Arena Pharmaceutical Inc (NASDAQ:ARNA, ARNA message board) announced an addition to its research and development pipeline, a new treatment for pulmonary arterial hypertension.
Top Angel Investors of New England: An Innovation Slideshow
Investment Philosophy: "Invest in dynamic entrepreneurs in fields I like and understand. I look for some barriers to entry (IP), and if successful the potential for the company to be a large player. I try to stay away from small niche plays." ...
Sucampo Pharma: An Undervalued Biopharma With Upcoming Catalysts
Another recent example of a strong catalyst price moving event was when Arena Pharma (ARNA) saw its stock price rise from the low $2 range to over $3.50 a share before the ADCOM for its weight loss drug, Belviq, and a gap up in price from $3.66 to $7 ...
Vivus Pharmaceuticals (NASDAQ:VVUS) Falls on Readjusted Sales Expectations
The drug also comes out with a warning on cardio-vascular risks as the company has not completed the trials to prove safety. Competitor Arena Pharmaceuticals, Inc (NASDAQ:ARNA) is just starting a post-market trial to assess heart and lung risk of the drug.
How home automation could save cable companies
Cable companies such as Comcast and Cox need to take a good look at their technology as streaming services Netflix and Hulu take away their profits.
America's Richest Cities
Median household income in the United States declined for the second straight year, according to data released by the U.S. Census Bureau last month.
Novartis delays restart of Lincoln production
Novartis said Thursday that restarting production at its plant east of Lincoln is taking longer than expected, and it is unlikely the company will ship any over-the-counter drugs out of the plant this year. "Manufacturing drugs, whether they are ...
Women's Fashion Ad Indicator: New bull 2013
Look beyond the so-called “war on women” rhetoric in the political arena where we see men fighting to control women's issues.
NPS Pharmaceuticals: Buy If There Is A Dip
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) shares were up nearly 20% on news that the FDA briefing document may favor approval of Gattex.
Biotech Stock Mailbag: Sarepta Bear Story, Vertex, Osiris
BOSTON ( TheStreet) -- I heard from a few Sarepta Therapeutics (SRPT) skeptics on Wednesday after the announcement of the 48-week eteplirsen data.